- Home
- DOUG vs MDXH Comparison
DOUG vs MDXH Comparison
Compare DOUG & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DOUG
- MDXH
- Stock Information
- Founded
- DOUG 1911
- MDXH 2003
- Country
- DOUG United States
- MDXH Belgium
- Employees
- DOUG N/A
- MDXH N/A
- Industry
- DOUG Building operators
- MDXH
- Sector
- DOUG Real Estate
- MDXH
- Exchange
- DOUG Nasdaq
- MDXH Nasdaq
- Market Cap
- DOUG 161.5M
- MDXH 141.1M
- IPO Year
- DOUG N/A
- MDXH 2021
- Fundamental
- Price
- DOUG $2.84
- MDXH $4.75
- Analyst Decision
- DOUG
- MDXH Buy
- Analyst Count
- DOUG 0
- MDXH 1
- Target Price
- DOUG N/A
- MDXH $6.00
- AVG Volume (30 Days)
- DOUG 544.7K
- MDXH 182.2K
- Earning Date
- DOUG 11-05-2025
- MDXH 11-05-2025
- Dividend Yield
- DOUG N/A
- MDXH N/A
- EPS Growth
- DOUG N/A
- MDXH N/A
- EPS
- DOUG N/A
- MDXH N/A
- Revenue
- DOUG $1,034,406,000.00
- MDXH $98,953,000.00
- Revenue This Year
- DOUG $17.61
- MDXH $24.40
- Revenue Next Year
- DOUG N/A
- MDXH $22.29
- P/E Ratio
- DOUG N/A
- MDXH N/A
- Revenue Growth
- DOUG 8.69
- MDXH 22.56
- 52 Week Low
- DOUG $1.35
- MDXH $1.35
- 52 Week High
- DOUG $3.20
- MDXH $4.94
- Technical
- Relative Strength Index (RSI)
- DOUG 50.90
- MDXH 73.62
- Support Level
- DOUG $2.69
- MDXH $4.51
- Resistance Level
- DOUG $3.01
- MDXH $4.94
- Average True Range (ATR)
- DOUG 0.17
- MDXH 0.29
- MACD
- DOUG -0.02
- MDXH -0.00
- Stochastic Oscillator
- DOUG 31.00
- MDXH 86.99
About DOUG Douglas Elliman Inc.
Douglas Elliman Inc is a real estate company. It offers sales, rentals, and new development to mortgages and title insurance, among other services related to real estate. Business is engaged in two operating segments Real Estate Brokerage and Corporate and other. The firm generates income from Commission and other brokerage revenue from existing home sales, Commission and other brokerage income from development marketing, Property management revenue and Title fees. It derives revenue from Real Estate Brokerage segment.
About MDXH MDxHealth SA
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.